Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis

• Published in: Oncotarget Vol. 8; no. 26; pp. 42602 - 42612
• Main Authors: Zhang, Xuerui, Huo, Lina, Jin, Haibo, Han, Yuheng, Wang, Jie, Zhang, Yanjun, Lai, Xinghuan, Le, Ziwei, Zhang, Jing, Hua, Zichun
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 27.06.2017
• Subjects: Animals; Annexin A5 - pharmacology; Apoptosis - drug effects; Disease Models, Animal; Female; Melanoma, Experimental - blood supply; Melanoma, Experimental - drug therapy; Melanoma, Experimental - pathology; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic - drug therapy; Neovascularization, Pathologic - pathology; Random Allocation; Research Paper; apoptosis; Annexin V; necrosis; tumor angiogenesis
• DOI: 10.18632/oncotarget.16645
• ISSN: 1949-2553

Annexin V, a protein with high affinity to phosphatidylserine (PS) in a calcium dependent manner, has been widely used to probe apoptosis. Annexin V in inhibiting engulfment of apoptotic cells by macrophages had been reported to increase the immunogenicity of tumor cells undergoing apoptosis. However, far less is known about its multiple properties, especially in cancer therapies. Here we found that Annexin V had a good anti-tumor activity in murine melanomaxenograft model. Treatment with Annexin V showed significant reduction in tumor size and remarkable tumor necrosis areas. The serum level of VEGF was downregualted by Annexin V both in normal mice and mice bearing tumor, suggesting that its new role on impeding tumor angiogenesis. In Silico analysis using Oncomine database, we also found the negative correlation of AnnexinV and VEGF both in skin and melanoma. The decreased Annexin V expression shows linearity relation with the elevated VEGF expression. These data provided a possibility that Annexin V can be used as a novel angiogenesis inhibitor in tumor therapy.